BSE Live
Feb 20, 14:00Prev. Close
888.70
Open Price
885.00
Bid Price (Qty.)
886.50 (17)
Offer Price (Qty.)
887.30 (157)
NSE Live
Feb 20, 14:00Prev. Close
888.30
Open Price
884.15
Bid Price (Qty.)
886.95 (2)
Offer Price (Qty.)
887.30 (1)
| Key Financial Ratios of Natco Pharma (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 40.64 | 32.16 | 23.01 | 20.53 | 19.01 | |
| Diluted EPS (Rs.) | 40.64 | 32.16 | 22.91 | 20.53 | 19.01 | |
| Cash EPS (Rs.) | 53.42 | 38.87 | 28.05 | 23.88 | 24.08 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 256.08 | 221.56 | 173.42 | 151.56 | 125.58 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 256.08 | 221.56 | 173.42 | 151.56 | 125.58 | |
| Revenue from Operations/Share (Rs.) | 248.32 | 223.41 | 210.54 | 166.96 | 163.31 | |
| PBDIT/Share (Rs.) | 68.71 | 59.29 | 51.77 | 38.27 | 33.82 | |
| PBIT/Share (Rs.) | 54.49 | 50.08 | 44.72 | 33.16 | 28.18 | |
| PBT/Share (Rs.) | 40.41 | 39.01 | 32.64 | 25.77 | 23.14 | |
| Net Profit/Share (Rs.) | 39.20 | 29.66 | 21.00 | 18.77 | 18.44 | |
| NP After MI And SOA / Share (Rs.) | 40.50 | 31.06 | 22.91 | 19.14 | 19.01 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 27.67 | 26.53 | 24.58 | 22.92 | 20.71 | |
| PBIT Margin (%) | 21.94 | 22.41 | 21.23 | 19.86 | 17.25 | |
| PBT Margin (%) | 16.27 | 17.46 | 15.50 | 15.43 | 14.16 | |
| Net Profit Margin (%) | 15.78 | 13.27 | 9.97 | 11.24 | 11.29 | |
| NP After MI And SOA Margin (%) | 16.31 | 13.90 | 10.88 | 11.46 | 11.64 | |
| Return on Networth/Equity (%) | 15.91 | 14.15 | 13.47 | 12.65 | 15.18 | |
| Return on Capital Employed (%) | 13.87 | 11.62 | 9.77 | 9.22 | 10.41 | |
| Return on Assets (%) | 9.72 | 8.59 | 6.65 | 6.60 | 7.56 | |
| Total Debt/Equity (X) | 0.31 | 0.27 | 0.54 | 0.46 | 0.56 | |
| Asset Turnover Ratio (%) | 59.62 | 61.79 | 61.13 | 57.60 | 64.98 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.17 | 1.18 | 0.97 | 1.22 | 1.28 | |
| Quick Ratio (X) | 0.64 | 0.60 | 0.54 | 0.79 | 0.75 | |
| Inventory Turnover Ratio (X) | 3.75 | 4.08 | 4.52 | 4.71 | 4.50 | |
| Dividend Payout Ratio (NP) (%) | 12.34 | 16.09 | 17.46 | 15.67 | 10.52 | |
| Dividend Payout Ratio (CP) (%) | 9.13 | 12.41 | 13.35 | 12.37 | 8.11 | |
| Earnings Retention Ratio (%) | 87.66 | 83.91 | 82.54 | 84.33 | 89.48 | |
| Cash Earnings Retention Ratio (%) | 90.87 | 87.59 | 86.65 | 87.63 | 91.89 | |
| Coverage Ratios | ||||||
| Interest Coverage Ratios (%) | 5.72 | 4.52 | 5.33 | 4.48 | 5.59 | |
| Interest Coverage Ratios (Post Tax) (%) | 5.72 | 4.52 | 5.33 | 4.48 | 5.59 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 7,269.94 | 2,825.87 | 1,629.52 | 1,281.85 | 935.85 | |
| EV/Net Operating Revenue (X) | 8.81 | 3.82 | 2.47 | 2.46 | 2.04 | |
| EV/EBITDA (X) | 31.84 | 14.41 | 10.03 | 10.75 | 9.83 | |
| MarketCap/Net Operating Revenue (X) | 8.50 | 3.57 | 2.04 | 2.12 | 1.67 | |
| Retention Ratios (%) | 87.65 | 83.90 | 82.53 | 84.32 | 89.47 | |
| Price/BV (X) | 8.29 | 3.63 | 2.52 | 2.34 | 2.18 | |
| Price/Net Operating Revenue | 8.50 | 3.57 | 2.04 | 2.12 | 1.67 | |
| Earnings Yield | 0.02 | 0.04 | 0.05 | 0.05 | 0.07 |
16.02.2026
Natco Pharma shares rise over 11% after firm receives approval to launch Semaglutide in India
16.02.2026
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
14.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
09.09.2025
Natco Pharma Standalone June 2025 Net Sales at Rs 1,192.70 crore, down 3.57% Y-o-Y